Cover image not available

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib

National Institute for Health and Clinical Excellence

Publication Data

Title Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib
Alternative Title Chronic myeloid leukaemia (imatinib intolerant/resistant) : dasatinib, nilotinib, imatinib
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 2012
Publication location Manchester
Language English

Descriptive Notes

Issued: January 2012.

Topics

Chronic myeloid leukemia :: Chemotherapy
Protein-tyrosine kinase :: Inhibitors
Imatinib

Catalogue Data

OBNB ID GBB586179
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99419061

ISBD

P1053 1 online resource (64 pages).
P1042 Includes bibliographical references.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2012. Publication and catalogue information, links to buy online and reader comments.